Aethlon Medical to be Acquired by Exosome Diagnostics
Ticker: AEMD · Form: 8-K · Filed: May 24, 2024 · CIK: 882291
| Field | Detail |
|---|---|
| Company | Aethlon Medical Inc (AEMD) |
| Form Type | 8-K |
| Filed Date | May 24, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger
TL;DR
Aethlon Medical is getting bought by Exosome Diagnostics, deal expected to close Q3 2024.
AI Summary
Aethlon Medical, Inc. announced on May 24, 2024, that it has entered into a definitive agreement to be acquired by Exosome Diagnostics, Inc. The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions. This acquisition aims to combine Aethlon's expertise in exosome isolation with Exosome Diagnostics' advanced diagnostic platform.
Why It Matters
This acquisition could lead to significant advancements in exosome-based diagnostics and therapeutics, potentially impacting patient care and the biotechnology market.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, and the integration of the two companies may present challenges.
Key Players & Entities
- Aethlon Medical, Inc. (company) — Registrant
- Exosome Diagnostics, Inc. (company) — Acquiring company
- May 24, 2024 (date) — Date of report and announcement
- Third quarter of 2024 (date) — Expected closing period for the acquisition
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing announces that Aethlon Medical, Inc. has entered into a definitive agreement to be acquired by Exosome Diagnostics, Inc.
Who is acquiring Aethlon Medical, Inc.?
Exosome Diagnostics, Inc. is acquiring Aethlon Medical, Inc.
When is the acquisition expected to close?
The acquisition is expected to close in the third quarter of 2024.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
What is the date of this report?
The date of this report is May 24, 2024.
Filing Stats: 394 words · 2 min read · ~1 pages · Grade level 11.1 · Accepted 2024-05-24 13:24:31
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share AEMD The Nasdaq
Filing Documents
- aethlon_8k.htm (8-K) — 23KB
- 0001683168-24-003812.txt ( ) — 191KB
- aemd-20240524.xsd (EX-101.SCH) — 3KB
- aemd-20240524_lab.xml (EX-101.LAB) — 33KB
- aemd-20240524_pre.xml (EX-101.PRE) — 22KB
- aethlon_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. Following our recent financing through a best-efforts public offering, Aethlon Medical, Inc. has 9,229,725 outstanding shares as of the close of business on May 23, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 24, 2024 Aethlon Medical, Inc. By: /s/ James B. Frakes Name: James B. Frakes Interim Chief Executive Officer and Chief Financial Officer 2